The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Andrew Tsai - Jefferies - Analyst
: Hey, good afternoon and thanks for taking my questions. Thanks for the updates. First question is what exactly can we expect you to say in the
interim release? Will it, will it be just a few sentences, or could it be something more detailed than that?
Question: Andrew Tsai - Jefferies - Analyst
: Mm okay. And I heard 2.2 points somewhere earlier in your prepared remarks. But is that for statistical significance just be just to clarify?
Question: Andrew Tsai - Jefferies - Analyst
: Got it. And then what threshold are you setting for the utility? What kind of placebo address at delta below what placebo address at delta? Will
you hit futility?
Question: Andrew Tsai - Jefferies - Analyst
: Very clear. Okay. Thank you and good luck on everything.
Question: Basma Radwan - Leerink Partners - Analyst
: Hi, good afternoon. This is Basma on for Mark. Thank you for taking our question regarding the interim readout. Are you going to be able to have
access to any other information such as baseline characteristics of the patients or [unli] in data of matters, changes for instance, or is it mainly going
to be the information related to the facility or not? Thank you.
Question: Basma Radwan - Leerink Partners - Analyst
: Thank you. That's very clear. Thank you.
Question: Unidentified Participant - Mizuho Securities USA - Analyst
: Hi, thanks for taking my question. It's Charles on for oil.
So I was curious if the DFC recommends no change. Would you continue to enrol to 300 or would that be that 400 or 340 number. Men. Yeah, thank
you.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 07, 2024 / 9:30PM, RLMD.OQ - Q3 2024 Relmada Therapeutics Inc Earnings Call
Question: Unidentified Participant - Mizuho Securities USA - Analyst
: Okay. Thanks.
For taking my question.
Question: Unidentified Participant 2 - Goldman Sachs - Analyst
: Hi team. This is Tala on for Andrea. Thanks for taking our questions. Two from us. First, from a statistical perspective, can you confirm you're not
taking a hit to alpha by conducting the interim analysis? And then secondly, just wondering if you have any updates on the percent screen failure
rates and reliance to compare to those from the prior studies. Thanks.
Question: Unidentified Participant 2 - Goldman Sachs - Analyst
: That's helpful. Thank you.
| 
